Literature DB >> 2982746

Identification of Marek's disease virus-specific antigens in Marek's disease lymphoblastoid cell lines using monoclonal antibody against virus-specific phosphorylated polypeptides.

K Ikuta, K Nakajima, M Naito, S H Ann, S Ueda, S Kato, K Hirai.   

Abstract

For identification of the antigens specific to Marek's disease virus (MDV) in virus-non-producer lymphoblastoid cell lines established from a tumor of Marek's disease (MD), hybridomas producing monoclonal antibodies (MAbs) against the antigens were isolated. Immunogens for preparation of the hybridomas were purified from the lysate of an MD-lymphoblastoid cell line, MSB1, by affinity chromatography coupled with chicken anti-MDV serum immunoglobulin G. Three of the MAbs obtained, MB1, MB2 and MB3, were specific to MDV by immunofluorescence test. An immunofluorescence test using MB2 antibody showed that immunofluorescence-positive cells in non-producer MD-lymphoblastoid line cells became detectable when the culture temperature was shifted from 41 degrees C to 33 degrees C or when treatment with 5-iodo-2-deoxyuridine (IUdR) was performed, indicating that the antigen reactive with MB2 antibody is an MDV-specific early antigen. This temperature shift or IUdR-treatment did not induce other MDV-specific antigens, such as late gene products of MDV, detected with MAbs. MB1 and MB2 antibodies immunoprecipitated 4 MDV-specific phosphorylated polypeptides with molecular weights (MWs) of 43,000 (43kd), 39kd, 36kd and 24kd from chick embryo fibroblasts productively infected with virulent MDV. In the place of 43kd, phosphorylated 44kd polypeptide was precipitated from avirulent MDV-infected fibroblasts. However, MB3 antibody did not precipitate any MDV-specific polypeptides from infected fibroblasts. These results suggest that the phosphorylated polypeptides are MDV-specific polypeptides predominantly expressed in non-producer MD-lymphoblastoid cell lines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982746     DOI: 10.1002/ijc.2910350219

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  The genome of a very virulent Marek's disease virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; D L Rock; G F Kutish
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Characterization of a very virulent Marek's disease virus mutant expressing the pp38 protein from the serotype 1 vaccine strain CVI988/Rispens.

Authors:  Lucy F Lee; Xiaoping Cui; Zhizhong Cui; Isabel Gimeno; Blanca Lupiani; Sanjay M Reddy
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

3.  Marek's disease virus unique genes pp38 and pp24 are essential for transactivating the bi-directional promoters for the 1.8 kb mRNA transcripts.

Authors:  Jiabo Ding; Zhizhong Cui; Lucy F Lee
Journal:  Virus Genes       Date:  2007-07-06       Impact factor: 2.332

4.  Marek's disease virus phosphorylated polypeptide pp38 alters transcription rates of mitochondrial electron transport and oxidative phosphorylation genes.

Authors:  Michael S Piepenbrink; Xinhui Li; Priscilla H O'Connell; Karel A Schat
Journal:  Virus Genes       Date:  2009-05-27       Impact factor: 2.332

5.  Characterization of reticuloendotheliosis virus-transformed avian T-lymphoblastoid cell lines infected with Marek's disease virus.

Authors:  W D Pratt; R W Morgan; K A Schat
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Recombinant Marek's disease virus (MDV)-derived lymphoblastoid cell lines: regulation of a marker gene within the context of the MDV genome.

Authors:  M S Parcells; R L Dienglewicz; A S Anderson; R W Morgan
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Identification with monoclonal antibodies of virus-specific DNA-binding proteins in the nuclei of cells infected with three serotypes of Marek's disease virus-related viruses.

Authors:  K Nakajima; K Ikuta; S Ueda; S Kato; K Hirai
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

Review 8.  Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.

Authors:  J M Wilson; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1995

9.  Transformation of T-lymphocyte subsets by Marek's disease herpesvirus.

Authors:  K A Schat; C L Chen; B W Calnek; D Char
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  The construction and characterization of the bi-directional promoter between pp38 gene and 1.8-kb mRNA transcripts of Marek's disease viruses.

Authors:  Ruiai Chen; Jiabo Ding; Bin Wang
Journal:  Virol J       Date:  2009-11-30       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.